Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Project Publications: University of California-San Diego: The Role of Reactive Oxygen Species and the Microbiome in Toxicant Induced Liver Fibrosis

Superfund Research Program

The Role of Reactive Oxygen Species and the Microbiome in Toxicant Induced Liver Fibrosis

Project Leader: David A. Brenner
Co-Investigator: Rohit Loomba
Grant Number: P42ES010337
Funding Period: 2017-2022
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Project-Specific Links

Connect with the Grantees

Visit the grantee's eNewsletter page Visit the grantee's Twitter page Visit the grantee's Instagram page Visit the grantee's Facebook page Visit the grantee's Video page

Publications

2022

  • Carvalho-Gontijo R, Han C, Zhang L, Zhang V, Hosseini M, Mekeel K, Schnabl B, Loomba R, Karin M, Brenner DA, Kisseleva T. 2022. Metabolic injury of hepatocytes promotes progression of NAFLD and AALD. Semin Liver Dis 42(3):233-249. doi:10.1055/s-0042-1755316 PMID:36001995
  • Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. 2022. Noninvasive risk stratification for nonalcoholic fatty liver disease among living liver donor candidates: A proposed algorithm. Liver Transpl 28(4):670-677. doi:10.1002/lt.26365 PMID:34753223
  • Gao H, Jin Z, Bandyopadhyay G, Rocha KC, Liu X, Zhao H, Zhang D, Jouihan H, Pourshahian S, Kisseleva T, Brenner DA, Ying W, Olefsky J. 2022. MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH. Cell Metab 34(7):978-990. doi:10.1016/j.cmet.2022.05.008 PMID:35700738 PMCID:PMC9262870
  • Gao H, Jin Z, Bandyopadhyay G, Wang G, Zhang D, Rocha KC, Liu X, Zhao H, Kisseleva T, Brenner DA, Karin M, Ying W. 2022. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis. Cell Metab 34(8):1201-1213. doi:10.1016/j.cmet.2022.07.006 PMID:35921818 PMCID:PMC9365100
  • Huang D, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez S, Gupta H, Sirlin CB, Marks RM, Loomba R. 2022. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 55(7):820-827. doi:10.1111/apt.16844 PMID:35229334
  • Liu Y, Meric G, Havulinna AS, Teo SM, Aberg F, Ruuskanen MO, Sanders JG, Zhu Q, Tripathi A, Verspoor K, Cheng S, Jain M, Jousilahti P, Vazquez-Baeza Y, Loomba R, Lahti L, Niiranen TJ, Salomaa VV, Knight R, Inouye M. 2022. Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metab 34(5):719-730. doi:10.1016/j.cmet.2022.03.002 PMID:35354069 PMCID:PMC9097589
  • Qin Y, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, Sanders JG, Valsta LM, Brozynska M, Zhu Q, Tripathi A, Vazquez-Baeza Y, Loomba R, Cheng S, Jain M, Niiranen TJ, Lahti L, Knight R, Salomaa VV, Inouye M, Meric G. 2022. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat Genet 54:PMID:35115689
  • Rowe IA, Wong VW, Loomba R. 2022. Treatment candidacy for pharmacologic therapies for NASH. Clin Gastroenterol Hepatol 20:P1209-1217. doi:10.1016/j.cgh.2021.03.005 PMID:33711479 PMCID:PMC8908435
  • Sinakos E, Liava C, Loomba R. 2022. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. Ann Gastroenterol 35(3):213-225. doi:10.20524/aog.2022.0704 PMID:35599922 PMCID:PMC9062842
  • Tamaki N, Ajmera VH, Loomba R. 2022. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 18:doi:10.1038/s41574-021-00584-0 PMID:34815553 PMCID:PMC9012520
  • Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N. 2022. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 20:1171-1173. doi:10.1016/j.cgh.2021.07.021 PMID:34280550 PMCID:PMC8761224
  • Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB and Loomba R. 2022. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 71:983-990. doi:10.1136/gutjnl-2021-324264 PMID:33883248 PMCID:PMC8594562
  • Tapper EB, Ufere NN, Huang DQ, Loomba R. 2022. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 55(9):doi:10.1111/apt.16831 PMID:35235219

2021

  • Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton MS, Fowler K, Sirlin C, Loomba R. 2021. Optimal threshold of controlled attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard. Clin Infect Dis 72(12):doi:10.1093/cid/ciaa429 PMID:32975278 PMCID:PMC8204791
  • Ajmera VH, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. 2021. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. Aliment Pharmacol Ther 54(1):doi:10.1111/apt.16392 PMID:33975381 (ahead of print)
  • Ajmera VH, Loomba R. 2021. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 50:doi:10.1016/j.molmet.2021.101167 PMID:33460786 PMCID:PMC8324681
  • Ajmera VH, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Sriram K, Insel PA, Collier S, Richards L, Loomba R. 2021. MIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. Contemp Clin Trials 103:doi:10.1016/j.cct.2021.106330 PMID:33631357 PMCID:PMC7899027
  • Byra M, Han A, Boehringer AS, Zhang YN, O'Brien WD, Erdman JW, Loomba R, Sirlin C, Andre MP. 2021. Liver fat assessment in multiview sonography using transfer learning with convolutional neural networks. J Ultrasound Med 41(1):doi:10.1002/jum.15693 PMID:33749862 (ahead of print)
  • Cariou B, Byrne CD, Loomba R, Sanyal AJ. 2021. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 23:1069-1083. doi:10.1111/dom.14322 PMID:33464677 PMCID:PMC8248154
  • Caussy C, Aubin A, Loomba R. 2021. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep 12:15. doi:10.1007/s11892-021-01383-7 PMID:33742318
  • Dhar D, Loomba R. 2021. Emerging metabolic and transcriptomic signature of PNPLA3-Associated NASH. Hepatology 73:PMID:33544416
  • Haas ME, Friedman SN, Wang M, Emdin CA, Ajmera VH, Simon TG, Homburger JR, Guo X, Budoff M, Corey K, Zhou AY, Philippakis A, Ellinor PT, Loomba R, Batra P, Khera AV, Pirruccello JP. 2021. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom 1(3):doi:10.1016/j.xgen.2021.100066 PMID:34957434 PMCID:PMC8699145
  • Hagstrom H, Adams LA, Allen AM, Byrne CD, Chang Y, Gronbaek H, Ismail M, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Aberg F. 2021. Administrative coding in electronic health care record-based research of NAFLD: An expert panel consensus statement. Hepatology 74:474-482. doi:10.1002/hep.31726 PMID:33486773 PMCID:PMC8515502
  • Huang DQ, El-Serag HB, Loomba R. 2021. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223-238. doi:10.1038/s41575-020-00381-6 PMID:33349658 PMCID:PMC8016738
  • Jiao N, Loomba R, Yang Z, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. 2021. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics doi:10.1152/physiolgenomics.00011.2021 PMID:34151600
  • Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. 2021. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70:1946-1953. doi:10.1136/gutjnl-2020-322976 PMID:33214165 PMCID:PMC8131405
  • Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wong VW, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. 2021. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161:1657-1669. doi:10.1053/j.gastro.2021.07.049 PMID:34602251 PMCID:PMC8819923
  • Loomba R. 2021. MRI-proton density fat fraction treatment response criteria in nonalcoholic steatohepatitis. Hepatology 73:881-883. doi:10.1002/hep.31624 PMID:33179266 PMCID:PMC8221026
  • Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. 2021. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 73:126-143. doi:10.1002/hep.31523 PMID:32794259 PMCID:PMC7898628
  • Loomba R, Ratziu V, Harrison SA. 2021. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162(3):doi:10.1053/j.gastro.2021.10.051 PMID:34822801
  • Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. 2021. Systematic review and network meta-analysis: Comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 54(7):880-889. doi:10.1111/apt.16583 PMID:34435378
  • Park JG, Jung J, Loomba R. 2021. Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Author's reply. Aliment Pharmacol Ther 52(2):PMID:34170539
  • Park JG, Jung J, Verma KK, Kang M, Madamba E, Lopez S, Yonan AQ, Liu A, Bettencourt R, Sirlin C, Loomba R. 2021. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther doi:10.1111/apt.16324 PMID:33764550
  • Rosenthal SB, Liu X, Ganguly S, Dhar D, Pasillas M, Ricciardelli E, Li RZ, Troutman T, Kisseleva T, Glass CK, Brenner DA. 2021. Heterogeneity of HSCs in a mouse model of NASH. Hepatology 74(2):667-685. doi:10.1002/hep.31743 PMID:33550587 PMCID:PMC8346581
  • Ruuskanen MO, Aberg F, Mannisto V, Havulinna AS, Meric G, Liu Y, Loomba R, Vazquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa VV, Jain M, Knight R, Lahti L, Niiranen TJ. 2021. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 13:1-22. doi:10.1080/19490976.2021.1888673 PMID:33651661 PMCID:PMC7928040
  • Sharpton SR, Schnabl B, Knight R, Loomba R. 2021. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab 33(1):21-32. doi:10.1016/j.cmet.2020.11.010 PMID:33296678 PMCID:PMC8414992
  • Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin C, Loomba R. 2021. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 19(11):2274-2283.e5. doi:10.1016/j.cgh.2020.08.061 PMID:32882428 PMCID:PMC7914285
  • Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. 2021. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology 75(3):doi:10.1002/hep.32145 PMID:34496054
  • Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. 2021. Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of Hepatitis C virus. Hepatol Commun PMID:34676692
  • Tamaki N, Munaganuru N, Jung J, Valasek MA, Behling C, Loomba R, Yonan AQ, Bettencourt R, Ajmera VH. 2021. Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD. Clin Gastroenterol Hepatol 19(12):doi:10.1016/j.cgh.2020.11.005 PMID:33157318 PMCID:PMC8438785
  • Vilarinho S, Ajmera VH, Zheng M, Loomba R. 2021. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology 74(4):doi:10.1002/hep.32047 PMID:34233030 PMCID:PMC8463418
  • Zhou R, Llorente C, Cao J, Zaramela LS, Zeng S, Gao B, Li S, Welch R, Huang F, Qi L, Pan C, Huang Y, Zhou P, Beussen I, Zhang Y, Bryam G, Fiehn O, Wang L, Liu E, Yu RT, Downes M, Evans RM, Goglin K, Fouts DE, Brenner DA, Bode L, Fan X, Zengler K, Schnabl B. 2021. Intestinal a1-2-fucosylation contributes to obesity and steatohepatitis in mice. Cell Mol Gastroenterol Hepatol 12(1):doi:10.1016/j.jcmgh.2021.02.009 PMID:33631374 PMCID:PMC8166943

2020

  • Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek MA, Behling C, Richards L, Sirlin C, Loomba R. 2020. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology 71(3):849-860. doi:10.1002/hep.30974 PMID:31556124 PMCID:PMC7828573
  • Balakrishnan M, Loomba R. 2020. The role of noninvasive tests for differentiating NASH from NAFL and diagnosing advanced fibrosis among patients with NAFLD. J Clin Gastroenterol 54(2):107-113. doi:10.1097/MCG.0000000000001284 PMID:31789757 PMCID:PMC7945957
  • Dhar D, Baglieri J, Kisseleva T, Brenner DA. 2020. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 13:doi:10.1177/1535370219898141 PMID:31924111 PMCID:PMC7016420
  • Dufour J, Caussy C, Loomba R. 2020. Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges. Gut 69:1877-1884. doi:10.1136/gutjnl-2019-319104 PMID:32381514 PMCID:PMC7497577
  • Han A, O'Brien WD, Erdman JW, Byra M, Heba E, Andre MP, Loomba R, Sirlin C. 2020. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat with radiofrequency ultrasound data using one-dimensional convolutional neural networks. Radiology 295:342-350. doi:10.1148/radiol.2020191160 PMID:32096706 PMCID:PMC7193902
  • Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW, Loomba R, Valasek MA, Sirlin C, O'Brien WD. 2020. Assessment of hepatic steatosis in nonalcoholic fatty liver disease by using quantitative US. Radiology 295:106-113. doi:10.1148/radiol.2020191152 PMID:32013792 PMCID:PMC7104700
  • Hydes TJ, Ravi S, Loomba R, Gray ME. 2020. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 26:doi:10.3350/cmh.2020.0067 PMID:32674529 PMCID:PMC7641567
  • Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Wisplinghoff H, Gao B, Kasper P, Roderburg C, Tacke F, Steffen H, Goeser T, Abraldes JG, Tu XM, Loomba R, Starkel P, Pride D, Fouts DE, Schnabl B. 2020. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology 159:1839-1852. doi:10.1053/j.gastro.2020.07.005 PMID:32652145
  • Long MT, Gandhi S, Loomba R. 2020. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism 111s:154259. doi:10.1016/j.metabol.2020.154259 PMID:32387227 PMCID:PMC7529729
  • Loomba R, Lim JK, Patton H, El-Serag HB. 2020. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 158:1822-1830. doi:10.1053/j.gastro.2019.12.053 PMID:32006545 PMCID:PMC8012107
  • Ma H, Yamamoto G, Xu J, Liu X, Karin D, Kim J, Alexandrov LB, Koyama Y, Nishio T, Benner CW, Heinz S, Rosenthal S, Liang S, Sun M, Karin G, Zhao P, Brodt P, Mckillop I, Quehenberger O, Dennis EA, Saltiel AR, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T. 2020. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol 72:946-959. doi:10.1016/j.jhep.2019.12.016 PMID:31899206 PMCID:PMC7167339
  • Mangla N, Ajmera VH, Caussy C, Sirlin C, Brouha SS, Bajwa-Dulai S, Madamba E, Bettencourt R, Richards L, Loomba R. 2020. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes. Clin Gastroenterol Hepatol 18(3):744-746. doi:10.1016/j.cgh.2019.05.003 PMID:31100460 PMCID:PMC6984972
  • Mouzaki M, Loomba R. 2020. An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol 18:270-280. doi:10.1007/s11938-020-00290-2 PMID:33716495 PMCID:PMC7946055
  • Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba E, Bettencourt R, Richards L, Raffatellu M, Dorrestein PC, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin C, Knight R, Downes M, Evans RM, Loomba R. 2020. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab 32:doi:10.1016/j.cmet.2020.10.015 PMID:33147487 PMCID:PMC7891106 (accepted for publication)
  • Sriram K, Loomba R, Insel PA. 2020. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenge. Proc Natl Acad Sci U S A 117:29274-29282. doi:10.1073/pnas.2009875117 PMID:33203679 PMCID:PMC7703541
  • Stender S, Loomba R. 2020. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology 71:777-779. doi:10.1002/hep.31113 PMID:31954067
  • Sun X, Seidman J, Zhao P, Troutman T, Spann N, Que X, Zhou F, Liao Z, Pasillas M, Yang X, Magida J, Kisseleva T, Brenner DA, Downes M, Evans RM, Saltiel AR, Tsimikas S, Glass CK, Witztum JL. 2020. Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis. Cell Metab 31(1):189-206. doi:10.1016/j.cmet.2019.10.014 PMID:31761566 PMCID:PMC7028360
  • Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac AF, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M. 2020. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab 2:1034-1045. doi:10.1038/s42255-020-0261-2 PMID:32839596 PMCID:PMC8018782
  • Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. 2020. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology 72:1819-1837. doi:10.1002/hep.31491 PMID:32740969 PMCID:PMC7435542
  • Xu J, Ma H, Liu X, Rosenthal SB, Baglieri J, Mccubbin R, Sun M, Koyama Y, Geoffroy C, Saijo K, Shang L, Nishio T, Maricic I, Kriefeldt M, Kusumanchi P, Roberts a, Zheng B, Kumar V, Zengler K, Pizzo D, Hosseini M, Contet C, Glass CK, Liangpunsakul S, Tsukamoto H, Gao B, Karin M, Brenner DA, Koob G, Kisseleva T. 2020. Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice. JCI Insight doi:10.1172/jci.insight.131277 PMID:32051339 PMCID:PMC7098802
  • Zhao P, Sun X, Chaggan C, Liao Z, Wong KI, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR. 2020. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367:doi:10.1126/science.aay0542 PMID:32029622 PMCID:PMC8012106 (accepted for publication)

2019

  • Baglieri J, Brenner DA, Kisseleva T. 2019. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int J Mol Sci 20(7):1723. doi:10.3390/ijms20071723 PMID:30959975 PMCID:PMC6479943
  • Castera L, Friedrich-Rust M, Loomba R. 2019. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 156(5):1264-1281. doi:10.1053/j.gastro.2018.12.036 PMID:30660725 PMCID:PMC7505052
  • Caussy C, Bhargava M, Villesen I, Gudmann N, Leeming D, Karsdal M, Faulkner C, Bao D, Liu A, Lo M, Bettencourt R, Bassirian S, Richards L, Brenner DA, Chen C, Sirlin C, Loomba R. 2019. Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology 70(1):127-141. doi:10.1002/hep.30610 PMID:30859582 PMCID:PMC6984974
  • Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu Z, Downes M, Evans RM, Brenner DA, Sirlin CB, Knight R, Loomba R. 2019. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 10:1406. doi:10.1038/s41467-019-09455-9 PMID:30926798 PMCID:PMC6440960
  • Liang S, Ma H, Zhong Z, Dhar D, Liu X, Xu J, Koyama Y, Nishio T, Karin D, Karin G, Mccubbin R, Zhang C, Hu R, Yang G, Chen L, Ganguly S, Lan T, Karin M, Kisseleva T, Brenner DA. 2019. NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice. Gastroenterology 156(4):1156-1172. doi:10.1053/j.gastro.2018.11.019 PMID:30445007 PMCID:PMC6409207
  • Loomba R, Adams L. 2019. The 20 Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. Hepatology 70(6):1885-1888. doi:10.1002/hep.30946 PMID:31520407 PMCID:PMC7504908
  • Mills P, Caussy C, Loomba R. 2019. Glyphosate Excretion is Associated with Steatohepatitis and Advanced Liver Fibrosis in Patients with Fatty Liver Disease. Clin Gastroenterol Hepatol 18(3):741-743. doi:10.1016/j.cgh.2019.03.045 PMID:30954713 PMCID:PMC6776714
  • Mouzaki M, Loomba R. 2019. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 12:1756284819858470. doi:10.1177/1756284819858470 PMID:31258623 PMCID:PMC6591661
  • Pai R, Kleiner D, Hart J, Adeyi O, Clouston A, Behling C, Jain D, Kakar S, Brahmania M, Burgart L, Batts K, Valasek MA, Torbenson M, Guindi M, Wang H, Ajmera VH, Adams L, Parker CE, Feagan B, Loomba R, Jairath V. 2019. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther 50(10):1100-1111. doi:10.1111/apt.15503 PMID:31583739 PMCID:PMC6817398
  • Wang L, Mazagova M, Pan C, Yang S, Brandl KL, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B, Schnabl B. 2019. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proc Natl Acad Sci U S A 116:15184-15193. doi:10.1073/pnas.1904360116 PMID:31289229 PMCID:PMC6660779

2018

  • Ajmera VH, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, Hooker J, Sy E, Behling C, Xu R, Middleton MS, Valasek MA, Faulkner C, Rizo E, Richards L, Sirlin CB, Loomba R. 2018. Magnetic Resonance Imaging Proton Density Fat Fraction Associates with Progression of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology 155(2):307-310. doi:10.1053/j.gastro.2018.04.014 PMID:29660324 PMCID:PMC6090543
  • Brenner DA. 2018. Of Mice and Men and Nonalcoholic Steatohepatitis. Hepatology 68(6):2059-2061. doi:10.1002/hep.30186 PMID:30033687 PMCID:PMC6398944
  • Brouha SS, Nguyen P, Bettencourt R, Sirlin CB, Loomba R. 2018. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: a prospective study. Eur Radiol 28:1345-1355. doi:10.1007/s00330-017-5075-6 PMID:29058029 PMCID:PMC6310479
  • Caussy C, Hsu CL, Lo M, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen C, Loomba R. 2018. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 68(3):918-932. doi:10.1002/hep.29892 PMID:29572891 PMCID:PMC6151296
  • Desai AP, Mohan P, Roubal AM, Bettencourt R, Loomba R. 2018. Geographic Variability in liver disease-related mortality rates in the United States. Am J Med 131:728-734. doi:10.1016/j.amjmed.2018.01.047 PMID:29496501 PMCID:PMC6090542
  • Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Starkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. 2018. Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice. Hepatology doi:10.1002/hep.29676 PMID:29159825 PMCID:PMC5962369
  • Kim J, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, Kaufman RJ, Saltiel AR, Karin M. 2018. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell 175(1):133-145. doi:10.1016/j.cell.2018.08.020 PMID:30220454 PMCID:PMC6159928
  • Tapper EB, Loomba R. 2018. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists. Hepatology 67:1657-1659. doi:10.1002/hep.29722 PMID:29222913 PMCID:PMC5906195
  • Tapper EB, Loomba R. 2018. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol 15:274-282. doi:10.1038/nrgastro.2018.10 PMID:29463906
  • Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. 2018. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15:397-411. doi:10.1038/s41575-018-0011-z PMID:29748586 PMCID:PMC6319369
  • Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin X, Wong J, Ding S, Seki E, Schnabl B, Hevener AL, Greenberg HB, Kisseleva T, Karin M. 2018. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560:198-203. doi:10.1038/s41586-018-0372-z PMID:30046112 PMCID:PMC6329306

2017

  • Drinane MC, Yaqoob U, Yu H, Luo F, Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S, Shah VH. 2017. Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight 2(24):92821. doi:10.1172/jci.insight.92821 PMID:29263300 PMCID:PMC5752303
  • Kim RG, Loomba R, Prokop LJ, Singh S. 2017. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 15(10):1521-1530. doi:10.1016/j.cgh.2017.04.039 PMID:28479502 PMCID:PMC5605397
  • Reinders ME, Wardi G, Bettencourt R, Bouland D, Bazick J, Mendler M, Vodkin I, Kalmaz D, Savides T, Brenner DA, Sell RE, Loomba R. 2017. Increased risk of death, in the hospital and outside the intensive care unit, for patients with cirrhosis after cardiac arrest. Clin Gastroenterol Hepatol 15(11):1808-1810. doi:10.1016/j.cgh.2017.05.044 PMID:28602970 PMCID:PMC5723019
  • Shalapour S, Lin X, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner CW, Anstee QM, Karin M. 2017. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551(7680):340-345. doi:10.1038/nature24302 PMID:29144460 PMCID:PMC5884449
  • Xu J, Ma H, Liang S, Sun M, Karin G, Koyama Y, Hu R, Quehenberger O, Davidson NO, Dennis EA, Kisseleva T, Brenner DA. 2017. The role of human CYP2E1 in liver inflammation and fibrosis. Hepatol Commun 1:1043-1057. doi:10.1002/hep4.1115 PMID:29404441 PMCID:PMC572140
Back
to Top